We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




RT-LAMP Assay Developed for SARS-CoV-2

By LabMedica International staff writers
Posted on 20 Apr 2020
SARS-CoV-2 is the causative viral pathogen of COVID-19, and diagnosis of COVID-19 can be done through CT scan of suspicious patients and a confirmatory laboratory test is performed using published real-time quantitative polymerase chain reaction (RT-qPCR) methods. More...


Although RT-qPCR methods are used as the gold-standard for detection of pathogens due to its high sensitivity and specificity, it still have some caveats. To overcome any restriction of RT-qPCR and still detect pathogens’ nucleic acids, isothermal amplification methods have been developed. Among such methods, Loop-mediated isothermal amplification (LAMP) method has some advantages to be applied for point-of-care test (POCT). Well optimized LAMP assay shows sensitivity comparable to that of PCR, less than 10 copies per reaction.

Scientists at the Korea Research Institute of Chemical Technology (Daejeon, Republic of Korea) and their colleagues developed and evaluated RT-LAMP assays to detect genomic RNA of SARS-CoV-2. The team used SARS-CoV-2 viral RNA that was prepared as previously described. hCoV-229E and hCoV-OC43 viral RNA were isolated from culture media of infected MRC-5 cells and MERS-CoV RNA was isolated from cell pellet lysate of infected Vero cells. To evaluate genomic copy number of viral RNAs, dilutions of standard RNAs and viral RNAs in TE buffer were subjected to one-step RT-qPCR. RT-qPCR reactions were carried out using a LightCycler 96 instrument (Roche Molecular Systems, Inc, Pleasanton, CA, USA).

The team reported that RT-LAMP assays used in their study can detect as low as 100 copies of SARS-CoV-2 RNA. Five out of seven primer sets showed specific amplification for at least one replicate of duplicate with cDNA concentration corresponding to 1.7 x 101 copies of input RNA. Cross-reactivity of RT-LAMP assays to other human Coronaviruses was not observed. The lauco crystal violet (LCV) method was applied to achieve colorimetric detection of LAMP reaction for their RT-LAMP assay so that the tests potentially performed in higher throughput.

The authors concluded that they have developed highly specific RT-LAMP assays for detection of SARS-CoV-2. The results of these RT-LAMP assays can be detected within 30 minutes after amplification reaction began. In addition, they provided optimized reaction conditions to which LCV colorimetric detection method is applied that can be used for point-of-care tests. The study was published on April 7, 2020 in The Journal of Molecular Diagnostics.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.